메뉴 건너뛰기




Volumn 33, Issue 16, 2012, Pages 2088-2097

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients

Author keywords

ACE inhibitor; ARB; Hypertension; Meta analysis; Mortality

Indexed keywords

AMLODIPINE; ATENOLOL; BENDROFLUMETHIAZIDE; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; TELMISARTAN; VALSARTAN;

EID: 84863807562     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs075     Document Type: Article
Times cited : (383)

References (46)
  • 1
    • 0037010474 scopus 로고    scopus 로고
    • Comparative Risk Assessment Collaborating G. Selected major risk factors and global and regional burden of disease
    • Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Comparative Risk Assessment Collaborating G. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-1360.
    • (2002) Lancet , vol.360 , pp. 1347-1360
    • Ezzati, M.1    Lopez, A.D.2    Rodgers, A.3    Vander Hoorn, S.4    Murray, C.J.5
  • 3
    • 0347423198 scopus 로고    scopus 로고
    • National Heart L, Blood I, National High Blood Pressure Education Program Coordinating C. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Joint National Committee on Prevention DE, Treatment of High Blood Pressure. National Heart L, Blood I, National High Blood Pressure Education Program Coordinating C. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-1252.
    • (2003) Hypertension , vol.42 , pp. 1206-1252
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3    Cushman, W.C.4    Green, L.A.5    Izzo, Jr.J.L.6    Jones, D.W.7    Materson, B.J.8    Oparil, S.9    Wright, Jr.J.T.10    Roccella, E.11
  • 4
    • 0017319491 scopus 로고
    • The biochemistry of the renin-angiotensin system and its role in hypertension
    • Skeggs LT, Dorer FE, Kahn JR, Lentz KE, Levine M. The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med 1976;60: 737-748.
    • (1976) Am J Med , vol.60 , pp. 737-748
    • Skeggs, L.T.1    Dorer, F.E.2    Kahn, J.R.3    Lentz, K.E.4    Levine, M.5
  • 6
    • 0025913812 scopus 로고
    • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators
    • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
    • (1991) N Engl J Med , vol.325 , pp. 293-302
  • 7
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
    • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
    • (2000) N Engl J Med , vol.342 , pp. 145-153
    • Yusuf, S.1    Sleight, P.2    Pogue, J.3    Bosch, J.4    Davies, R.5    Dagenais, G.6
  • 8
    • 0042330455 scopus 로고    scopus 로고
    • Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
    • Fox KM, Investigators EUtOrocewPiscAd. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
    • (2003) Lancet , vol.362 , pp. 782-788
    • Fox, K.M.1
  • 18
    • 0030922816 scopus 로고    scopus 로고
    • Bias in meta-analysis detected by a simple, graphical test
    • Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
    • (1997) BMJ , vol.315 , pp. 629-634
    • Egger, M.1    Davey Smith, G.2    Schneider, M.3    Minder, C.4
  • 19
    • 66249127233 scopus 로고    scopus 로고
    • Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)
    • Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H, Investigators H-C. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009;30: 1203-1212.
    • (2009) Eur Heart J , vol.30 , pp. 1203-1212
    • Kasanuki, H.1    Hagiwara, N.2    Hosoda, S.3    Sumiyoshi, T.4    Honda, T.5    Haze, K.6    Nagashima, M.7    Yamaguchi, J.8    Origasa, H.9    Urashima, M.10    Ogawa, H.11
  • 20
    • 55349147316 scopus 로고    scopus 로고
    • Group C-JT. ARB candesartan and CCB amlodipine in hypertensive patients: The CASE-J trial
    • Ogihara T, Fujimoto A, Nakao K, Saruta T, Group C-JT. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther 2008;6:1195-1201.
    • (2008) Expert Rev Cardiovasc Ther , vol.6 , pp. 1195-1201
    • Ogihara, T.1    Fujimoto, A.2    Nakao, K.3    Saruta, T.4
  • 21
    • 73849084830 scopus 로고    scopus 로고
    • Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study
    • Sawada T, Yamada H, Dahlof B, Matsubara H, Group KHS. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009;30:2461-2469.
    • (2009) Eur Heart J , vol.30 , pp. 2461-2469
    • Sawada, T.1    Yamada, H.2    Dahlof, B.3    Matsubara, H.4
  • 26
    • 24644443331 scopus 로고    scopus 로고
    • Prevention of cardiovascular events with an antihy-pertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
    • Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Investigators A. Prevention of cardiovascular events with an antihy-pertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
    • (2005) Lancet , vol.366 , pp. 895-906
    • Dahlof, B.1    Sever, P.S.2    Poulter, N.R.3    Wedel, H.4    Beevers, D.G.5    Caulfield, M.6    Collins, R.7    Kjeldsen, S.E.8    Kristinsson, A.9    McInnes, G.T.10    Mehlsen, J.11    Nieminen, M.12    O'Brien, E.13    Ostergren, J.14    Investigators, A.15
  • 29
    • 0037534905 scopus 로고    scopus 로고
    • The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial
    • Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, Group SS. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
    • (2003) J Hypertens , vol.21 , pp. 875-886
    • Lithell, H.1    Hansson, L.2    Skoog, I.3    Elmfeldt, D.4    Hofman, A.5    Olofsson, B.6    Trenkwalder, P.7    Zanchetti, A.8
  • 30
    • 0001667151 scopus 로고    scopus 로고
    • Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
    • (2002) JAMA , vol.288 , pp. 2981-2997
    • Officers, A.1
  • 32
    • 20444427156 scopus 로고    scopus 로고
    • Morbidity and Mortality after Stroke, Epro-sartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES)
    • Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, Group MS. Morbidity and Mortality After Stroke, Epro-sartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-1226.
    • (2005) Stroke , vol.36 , pp. 1218-1226
    • Schrader, J.1    Luders, S.2    Kulschewski, A.3    Hammersen, F.4    Plate, K.5    Berger, J.6    Zidek, W.7    Dominiak, P.8    Diener, H.C.9    Group, M.S.10
  • 34
    • 11144355108 scopus 로고    scopus 로고
    • Japan Multicenter Investigation for Cardiovascular Diseases BSG. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial
    • Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C, Japan Multicenter Investigation for Cardiovascular Diseases BSG. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004;27:181-191.
    • (2004) Hypertens Res , vol.27 , pp. 181-191
    • Yui, Y.1    Sumiyoshi, T.2    Kodama, K.3    Hirayama, A.4    Nonogi, H.5    Kanmatsuse, K.6    Origasa, H.7    Iimura, O.8    Ishii, M.9    Saruta, T.10    Arakawa, K.11    Hosoda, S.12    Kawai, C.13
  • 35
    • 53049109468 scopus 로고    scopus 로고
    • Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial
    • Telmisartan Randomised AssessmeNt Study in ACEiswc DI, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-1183.
    • (2008) Lancet , vol.372 , pp. 1174-1183
    • Eiswc, D.I.1    Yusuf, S.2    Teo, K.3    Anderson, C.4    Pogue, J.5    Dyal, L.6    Copland, I.7    Schumacher, H.8    Dagenais, G.9    Sleight, P.10
  • 36
    • 33746863179 scopus 로고    scopus 로고
    • Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials
    • Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368:581-588.
    • (2006) Lancet , vol.368 , pp. 581-588
    • Dagenais, G.R.1    Pogue, J.2    Fox, K.3    Simoons, M.L.4    Yusuf, S.5
  • 37
    • 79952213953 scopus 로고    scopus 로고
    • Antihyper-tensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: A meta-analysis
    • Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihyper-tensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011;305:913-922.
    • (2011) JAMA , vol.305 , pp. 913-922
    • Thompson, A.M.1    Hu, T.2    Eshelbrenner, C.L.3    Reynolds, K.4    He, J.5    Bazzano, L.A.6
  • 38
    • 67650082354 scopus 로고    scopus 로고
    • Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
    • Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
    • (2009) BMJ , vol.338
    • Law, M.R.1    Morris, J.K.2    Wald, N.J.3
  • 40
    • 33747767282 scopus 로고    scopus 로고
    • Angiotensin receptor blockers may increase risk of myocar-dial infarction: Unraveling the ARB-MI paradox
    • Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocar-dial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-854.
    • (2006) Circulation , vol.114 , pp. 838-854
    • Strauss, M.H.1    Hall, A.S.2
  • 41
    • 79955667530 scopus 로고    scopus 로고
    • Angiotensin receptor blockers and risk of myocardial infarction: Meta-analyses and trial sequential analyses of 147 020 patients from randomised trials
    • Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011;342:d2234.
    • (2011) BMJ , vol.342
    • Bangalore, S.1    Kumar, S.2    Wetterslev, J.3    Messerli, F.H.4
  • 44
    • 79954933210 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: A meta-analysis of placebo-controlled clinical trials
    • Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T, Mancia G, Volpe M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens 2011;24:582-590.
    • (2011) Am J Hypertens , vol.24 , pp. 582-590
    • Tocci, G.1    Paneni, F.2    Palano, F.3    Sciarretta, S.4    Ferrucci, A.5    Kurtz, T.6    Mancia, G.7    Volpe, M.8
  • 45
    • 7444237666 scopus 로고    scopus 로고
    • Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
    • Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to T, Enalapril Study G. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-1961.
    • (2004) N Engl J Med , vol.351 , pp. 1952-1961
    • Barnett, A.H.1    Bain, S.C.2    Bouter, P.3    Karlberg, B.4    Madsbad, S.5    Jervell, J.6    Mustonen, J.7
  • 46
    • 61849163580 scopus 로고    scopus 로고
    • EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
    • Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, Group ES. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-137.
    • (2009) Eur J Cardiovasc Prev Rehabil , vol.16 , pp. 121-137
    • Kotseva, K.1    Wood, D.2    De Backer, G.3    De Bacquer, D.4    Pyorala, K.5    Keil, U.6    Group, E.S.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.